Navigation Links
Omthera Announces Waiver of Lock-Up Restriction
Date:7/11/2013

mpleted pharmacokinetic and Phase III clinical studies to investigate the safety and efficacy profile of Epanova™. In 2012 the Company reported positive results from its Phase III EVOLVE and ESPRIT trials, both of which were conducted under SPA agreements with the U.S. Food and Drug Administration. Omthera holds worldwide rights to Epanova™ under a license from Chrysalis Pharma AG, a privately held Swiss company that is the owner of the product. For more information, please visit http://www.omthera.com.

Important Information and Where to Find It

On June 13, 2013, the Company filed with the Securities and Exchange Commission (the "SEC") a definitive proxy statement in connection with the proposed transaction (the "Definitive Proxy Statement") and, on June 14, 2013, the Company commenced mailing of the Definitive Proxy Statement to its stockholders.  INVESTORS AND THE COMPANY'S STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE COMPANY.  Investors and stockholders may obtain free copies of the Definitive Proxy Statement and other documents (when available) that the Company files with the SEC at the SEC's website at http://www.sec.gov.  In addition, the Definitive Proxy Statement and other documents filed by the Company with the SEC may be obtained from the Company free of charge by directing a request to Omthera Pharmaceuticals, Inc., Attn: Christian S. Schade, Executive Vice President and Chief Financial Officer, 707 State Road, Princeton, New Jersey 08540.

Certain Information Concerning Participants

The Company and its directors and executive officers and certain other persons may be deemed to be partici
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
2. Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm
3. Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
4. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
5. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
6. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
7. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
8. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. CryoLife Announces Release Date and Teleconference Call Details for 2013 Second Quarter Financial Results
11. UM Ventures Announces Collaboration Between UM School Of Medicines Dr. Frank Robb and Fina Biosolutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014 /PRNewswire/ - Milestone Pharmaceuticals, Inc. today announced ... Melbourne, Australia of MSP-2017, ... treatment of paroxysmal supraventricular tachycardia (PSVT).  The results ... well tolerated at single doses up to and ... desirable PK properties including rapid onset, and validating ...
(Date:11/24/2014)... Nov. 24, 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced today that Sergio Traversa ... the LD MICRO "MAIN Event" Micro-Cap Growth Conference on ... at the Luxe Sunset Bel Air Hotel, which is ... Angeles, California . The presentation is ...
(Date:11/24/2014)... Theater, LLC, announced today that their technology will be ... Europe,s first simulation center, The ... Planner (SRP) and the Surgical Navigation Advanced Platform (SNAP) ... navigation and augmented reality capabilities in the operating room ... Department of Neurosurgery at Mount Sinai Health System in ...
Breaking Medicine Technology:Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 2Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 3Relmada Therapeutics To Present At LD MICRO Conference 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3
... Healthcare and,Laboratory Corporation of America(R) Holdings (LabCorp(R)) ... agreement to discuss future,possibilities to co-develop new ... diagnostics, metabolic syndrome, oncology and diabetes. Under ... new tests that,could make the biggest impact ...
... of the American Pain Society ... ... sustained pain relief from diabetic neuropathic pain (DNP),compared to placebo-treated patients, according ... (APS) in Tampa, Fla., "This is the first placebo-controlled trial of ...
Cached Medicine Technology:Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4
(Date:11/24/2014)... CO, and Philadelphia, PA (PRWEB) November 24, 2014 ... provider of care coordination and disease management services ... has chosen to implement Essette’s Medical Management software ... new Essette SaaS platform in a program to ... Essette suite includes Population Health Management, Care Management, ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 24, 2014 ... Trials Review, H2, 2014" provides data on the ... information and data relating to the clinical trials ... trial numbers and their recruitment status as per ... The databook offers a preliminary coverage of disease ...
(Date:11/23/2014)... (PRWEB) November 24, 2014 Tbdress.com ... be available online on Nov. 28, 2014. The special offer ... , Tbdress.com is one of the world’s largest women’s ... styles and colors. People can enjoy great discounts on that ... can enjoy free delivery (for orders above $89). , People ...
(Date:11/23/2014)... -- The holidays can be a challenge for families ... major meltdowns, an expert says. "Holidays with family ... when you have children with special needs, some care ... at University of the Sciences in Philadelphia, said in ... your hosts or visitors know what special requirements are ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers ... has announced its new collection of power suppliers. Additionally, ... quality power suppliers. All the new models come with ... lasts until Dec. 20, 2014. , SWAccessControl.com has thousands ... supporting it for a long time. It is very ...
Breaking Medicine News(10 mins):Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2
... on cells could prompt overeating, study suggests , THURSDAY, ... more evidence that dopamine -- a brain chemical associated ... role in obesity. , Researchers at the U.S. government,s ... obese rats have lower levels of dopamine D2 receptors ...
... Loss Narrows on Growth of Services Revenues, Higher Margins ... Outlook Improves for 2007 Net Results, POWAY, Calif., ... leading provider of medical diagnostic imaging systems,and services to ... for the third quarter and nine months ended,September 30, ...
... The 5th site in the,AZoNetwork portfolio builds on ... AZoNano.com - the A to Z of Nanotechnology and ... ( http://www.AZoOptics.com ) is the latest AZoNetwork,online knowledge base ... science, design and engineering community with a,continuously updating resource ...
... issued,today by the law firm of Schiffrin Barroway Topaz & ... action lawsuit was filed in the,United States District Court for ... of Aetna Inc. (NYSE: AET ) ("Aetna" or,the "Company") ... Period"). If you wish to discuss this action or ...
... steps to help members get the care they need, ... AET ) is making it,easier for members impacted by ... access employee assistance and,behavior health programs. In addition, the ... help them access care in San Diego,County, where many ...
... Mayo Clinic study due to be presented at the ... in San Diego this week shows that a chromosome ... identifying chromosomal genetic abnormalities associated with plasma cell malignancies. ... a patients prognosis and likelihood to respond to a ...
Cached Medicine News:Health News:Brain's 'Reward Chemical' May Help Spur Obesity 2Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 2Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 3Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 4Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 5Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 6Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 7Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 8Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 9Health News:AZoOptics.com - The A to Z of Optics Launched By AZoNetwork 2Health News:Shareholder Class Action Filed Against Aetna Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against Aetna Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:Aetna Reminds Members Affected by California Wildfires Where to Call for Help 2Health News:Aetna Reminds Members Affected by California Wildfires Where to Call for Help 3Health News:Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study 2
Sponge style scrub brush and nail cleaner is impregnated for antimicrobial cleaning....
BETASEPT® Scrub 4% is for surgical handscrubbing, healthcare personnel hand-washing, preoperative patient prepping and general skin degerming....
... Biosoft plus Neu Thera ... anti-infective alcohol hand sanitizer ... ingredients of the Neu-Thera ... been clinically proven to ...
... The use of waterless alcohol hand sanitizers ... are replacing soap and water as the ... per the 2002 CDC Draft Guidelines for ... of healthcare associated infections can be prevented ...
Medicine Products: